Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$33.72 - $47.33 $60,696 - $85,194
-1,800 Reduced 28.13%
4,600 $206,000
Q2 2024

Nov 01, 2024

BUY
$24.66 - $34.8 $44,388 - $62,639
1,800 Added 39.13%
6,400 $221,000
Q2 2024

Aug 09, 2024

BUY
$24.66 - $34.8 $157,824 - $222,719
6,400 New
6,400 $221,000
Q2 2023

Aug 08, 2023

SELL
$18.02 - $29.36 $174,794 - $284,792
-9,700 Reduced 57.4%
7,200 $198,000
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $182,182 - $428,922
16,900 New
16,900 $388,000
Q2 2022

Jul 21, 2022

BUY
$7.06 - $25.52 $118,608 - $428,736
16,800 New
16,800 $172,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Belvedere Trading LLC Portfolio

Follow Belvedere Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Belvedere Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belvedere Trading LLC with notifications on news.